Skip to content
Agentic OS
Menu

Intelligence / Healthtech / New Clinical Trials / UCB Biopharma SRL

Clinicaltrial registered13 Nov 2026

UCB Biopharma SRL

13 Nov 2026: Trial registered · A Study to Evaluate the Placental Transfer of Dapirolizumab Pegol to the Infant(s) From Pregnant Study Participants With Active Systemic Lupus Erythematosus Who Are Administered Dapirolizumab Pegol. Recorded in the ClinicalTrials.gov (US National Library of Medicine).

View the source record

Posted
13 Nov 2026
Title
A Study to Evaluate the Placental Transfer of Dapirolizumab Pegol to the Infant(s) From Pregnant Study Participants With Active Systemic Lupus Erythematosus Who Are Administered Dapirolizumab Pegol
Conditions
Systemic Lupus Erythematosus
Phase
Phase 1
Study Type
Interventional
Status
Not Yet Recruiting
Reference
NCT07934472
What this signal means

A new trial needs sites, patients, data capture, monitoring and regulatory partners for years.

  1. United States leads with 192 of 777, then China (171).
  2. 777 added in the 30 days to 18 Nov 2026.
Reach them with AOS

Find the decision makers at UCB Biopharma SRL

AOS maps the buying committee, finds verified work emails and drafts outreach that cites this clinical signal, for your approval.

Start free

Source: ClinicalTrials.gov (US National Library of Medicine), data to 18 Nov 2026. Trials first posted in the window whose lead sponsor is a company, worldwide. Device and diagnostic studies usually have no phase. AOS shows what the public record says; it does not verify or endorse the company.